Funding for this research was provided by:
Singapore Ministry of Education (MOE2017-T2-2-122)
Article History
Received: 31 August 2020
Accepted: 15 October 2020
First Online: 30 October 2020
Ethics approval and consent to participate
: NA.
: All authors concur with this publication.
: Ruowen Ge is the scientific founder of NovoBreeze Therapeutics Co. Ltd., Ningbo, China. Other authors declare no competing interest.